Study guide

Section 2.9: Non-linear and Multi-compartment Pharmacokinetics

Saudi Pharmacist Licensure Examination SPLE - Pharmacist

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

Section 0.1: About the Saudi Pharmacist Licensure Examination (SPLE) Section 0.2: How to Study and Prep for the SPLE

2 Chapter 1: Basic Biomedical Sciences

Section 1.1: Human Physiology & Pathophysiology Foundations Section 1.2: Medical Biochemistry & Enzymology Section 1.3: Medical Microbiology & Immunology Section 1.4: Molecular Genetics & Pharmacogenomics Foundations

3 Chapter 2: Pharmaceutical Sciences

Section 2.1: Medicinal Chemistry & Structure-Activity Relationships (SAR) Section 2.2: Drug ADME (Absorption, Distribution, Metabolism, Excretion) Section 2.3: General Pharmacology: Mechanisms of Drug Action Section 2.4: General Toxicology: Overdose, Antidotes & Adverse Drug Reactions (ADRs) Section 2.5: Pharmacognosy: Natural Products & Dietary Supplements Section 2.6: Basic Pharmaceutics & Dosage Form Design Section 2.7: Biopharmaceutics & Drug Delivery Systems Section 2.8: Applied Pharmacokinetics (PK): One-Compartment Models Section 2.9: Non-linear and Multi-compartment Pharmacokinetics Section 2.10: Sterile Compounding: Techniques & Quality Standards Section 2.11: Non-sterile Compounding & Product Formulation Section 2.12: Pharmaceutical Calculations: Dosing and Strengths Section 2.13: Pharmaceutical Calculations: Dilutions and Reconstitution Section 2.14: Pharmaceutical Calculations: Osmolarity, Milliequivalents, and Alligations

4 Chapter 3: Social, Behavioral, and Administrative Sciences

Section 3.1: Saudi Arabian Healthcare System & Public Health Policies Section 3.2: Pharmacoepidemiology & Post-Marketing Drug Surveillance Section 3.3: Pharmacovigilance & Drug Safety Monitoring in Saudi Arabia Section 3.4: Pharmacoeconomic Principles & Cost-Benefit Analysis Section 3.5: Pharmacy Management, Inventory, and Operations Section 3.6: Saudi Pharmacy Law & SFDA Regulations Section 3.7: Biostatistics, Clinical Trial Design & Literature Evaluation Section 3.8: Professional Ethics, Communication, and Dispensing Systems

5 Chapter 4: Clinical Sciences

Section 4.1: Drug Information Services & Evidence-Based Medicine Section 4.2: Clinical Pharmacokinetics & Therapeutic Drug Monitoring (TDM) Section 4.3: Clinical Pharmacogenomics & Personalized Therapeutics Section 4.4: Disease Prevention, Wellness, and Immunization Schedules Section 4.5: Patient Assessment & Physical Examination Interpretation Section 4.6: Clinical Pharmacology: Cardiovascular Disorders Section 4.7: Clinical Pharmacology: Renal & Urological Disorders Section 4.8: Clinical Pharmacology: Respiratory & Pulmonary Disorders Section 4.9: Clinical Pharmacology: Endocrine & Metabolic Disorders Section 4.10: Clinical Pharmacology: Infectious Diseases & Antimicrobial Stewardship Section 4.11: Clinical Pharmacology: Neurological & Psychiatric Disorders Section 4.12: Clinical Pharmacology: Oncology, Immunology, and Hematology Section 4.13: Clinical Pharmacology: Gastrointestinal & Hepatic Disorders Section 4.14: Therapeutic Decision-Making in Special Populations (Geriatrics, Pediatrics, Pregnancy, Lactation)

Section 2.9: Non-linear and Multi-compartment Pharmacokinetics

Key Takeaways Explain This Topic AI

Non-linear kinetics (saturable kinetics) occur when drug concentrations approach or exceed the metabolic enzyme capacity (Vmax), making clearance and half-life dose-dependent.

Phenytoin is the classic clinical exemplar of Michaelis-Menten kinetics, where a small dose increase can lead to a disproportionately large increase in plasma levels, risking severe toxicity.

For non-linear dosing, the daily dose rate (R) is calculated as R = (Vmax * Css) / (Km + Css), where Km is the Michaelis constant.

Multi-compartment models exhibit biphasic plasma concentration profiles, comprising a rapid distribution (alpha) phase and a slower elimination (beta) phase.

Serum level monitoring of multi-compartment drugs like digoxin or vancomycin must occur after the distribution phase is complete to avoid misleadingly high results.

Last updated: July 2026

Non-linear and Multi-compartment Pharmacokinetics

While one-compartment linear models are useful, many drugs clinically exhibit complex behaviors. These fall into two main categories: non-linear (saturable) kinetics , where pharmacokinetic parameters change with the administered dose, and multi-compartment kinetics , where drugs distribute into different tissues at different rates rather than equilibrating instantaneously.

Non-linear Pharmacokinetics (Michaelis-Menten Kinetics)

In linear pharmacokinetics, clearance ( C l Cl Cl ) and half-life ( t 1 / 2 t_{1/2} t 1/2 ​ ) are constant, meaning that doubling the dose results in an exact doubling of the steady-state plasma concentration. However, for drugs that undergo capacity-limited elimination, the metabolic enzymes or transport proteins can become saturated at therapeutic concentrations. This behavior is described by the Michaelis-Menten equation : − d C d t = V m a x ⋅ C K m + C -\frac{dC}{dt} = \frac{V_{max} \cdot C}{K_m + C} − d t d C ​ = K m ​ + C V ma x ​ ⋅ C ​

where V m a x V_{max} V ma x ​ is the maximum rate of drug elimination (metabolism) in mg/day \text{mg/day} mg/day , K m K_m K m ​ is the Michaelis constant (in mg/L \text{mg/L} mg/L ), representing the concentration at which the rate of elimination is exactly half of V m a x V_{max} V ma x ​ , and C C C is the plasma concentration of the drug.

Clinical Implications of Saturation Kinetics

First-Order Kinetics ( C ≪ K m C \ll K_m C ≪ K m ​ ): At low concentrations, the equation simplifies to − d C / d t ≈ ( V m a x ⋅ C ) / K m -dC/dt \approx (V_{max} \cdot C) / K_m − d C / d t ≈ ( V ma x ​ ⋅ C ) / K m ​ . The rate of elimination is proportional to concentration; clearance is constant, and kinetics are linear.

Mixed-Order Kinetics ( C ≈ K m C \approx K_m C ≈ K m ​ ): The rate of elimination is no longer directly proportional to concentration. The clearance decreases as the concentration rises.

Zero-Order Kinetics ( C ≫ K m C \gg K_m C ≫ K m ​ ): At high concentrations, the enzymes are fully saturated, and the equation simplifies to − d C / d t ≈ V m a x -dC/dt \approx V_{max} − d C / d t ≈ V ma x ​ . The drug is eliminated at a constant rate regardless of concentration. Clearance decreases and half-life increases with dose.

Phenytoin: The Classic Example

Phenytoin is the primary clinical example of Michaelis-Menten kinetics. The therapeutic range of phenytoin is 10 to 20 mcg/mL 10\text{ to }20\text{ mcg/mL} 10 to 20 mcg/mL , which overlaps with its typical K m K_m K m ​ value ( 4 to 6 mcg/mL 4\text{ to }6\text{ mcg/mL} 4 to 6 mcg/mL ). Thus, phenytoin metabolism is saturated within its normal clinical range. A small dose adjustment can lead to a massive, non-linear spike in serum concentration, leading to toxicity (nystagmus, ataxia, slurred speech).

Winter-Tozer Albumin Correction: In patients with hypoalbuminemia (serum albumin < 3.5 g/dL < 3.5\text{ g/dL} < 3.5 g/dL ) or end-stage renal disease, phenytoin protein binding is reduced, raising the active free fraction. The measured total phenytoin level must be adjusted using the Winter-Tozer equation : C a d j u s t e d = C m e a s u r e d 0.2 ⋅ Albumin + 0.1 C_{adjusted} = \frac{C_{measured}}{0.2 \cdot \text{Albumin} + 0.1} C a d j u s t e d ​ = 0.2 ⋅ Albumin + 0.1 C m e a s u re d ​ ​

Dosing Calculations for Phenytoin: To determine the steady-state concentration ( C s s C_{ss} C ss ​ ) achieved by a daily dose rate ( R R R , in mg/day \text{mg/day} mg/day of active drug): R = V m a x ⋅ C s s K m + C s s R = \frac{V_{max} \cdot C_{ss}}{K_m + C_{ss}} R = K m ​ + C ss ​ V ma x ​ ⋅ C ss ​ ​

To solve for the steady-state concentration ( C s s C_{ss} C ss ​ ): C s s = K m ⋅ R V m a x − R C_{ss} = \frac{K_m \cdot R}{V_{max} - R} C ss ​ = V ma x ​ − R K m ​ ⋅ R ​

Note on Salt Factor ( S S S ): Phenytoin sodium capsules have a salt factor of S = 0.92 S = 0.92 S = 0.92 , meaning only 92 % 92\% 92% of the dose is active phenytoin. Free phenytoin acid has S = 1.0 S = 1.0 S = 1.0 . The active daily dose rate is R = Dose ⋅ S ⋅ F R = \text{Dose} \cdot S \cdot F R = Dose ⋅ S ⋅ F .

Phenytoin Loading Dose Calculation: Loading Dose = V d ⋅ ( C t a r g e t − C i n i t i a l ) S ⋅ F \text{Loading Dose} = \frac{V_d \cdot (C_{target} - C_{initial})}{S \cdot F} Loading Dose = S ⋅ F V d ​ ⋅ ( C t a r g e t ​ − C ini t ia l ​ ) ​

Multi-compartment Pharmacokinetics

In a multi-compartment model (commonly a two-compartment model), the body is divided into:

Central Compartment: Consists of highly perfused tissues (blood, heart, liver, kidneys, lungs) that equilibrate with the drug rapidly.

Peripheral Compartment: Consists of poorly perfused tissues (skeletal muscle, adipose tissue, skin, bone) that equilibrate with the drug slowly.

Biphasic Concentration Decline

Following an intravenous bolus of a multi-compartment drug, a semi-log plot of plasma concentration versus time exhibits a biphasic decline:

Distribution ( α \alpha α ) phase: A rapid initial drop in plasma concentration as the drug transfers from the central compartment into the peripheral compartment.

Elimination ( β \beta β ) phase: A slower terminal decline where equilibrium between compartments is reached, and the decline in plasma concentration is driven primarily by drug elimination from the central compartment.

Clinical Monitoring Considerations (TDM)

For multi-compartment drugs like digoxin , vancomycin , and lithium , the distribution phase is prolonged.

If a blood sample is drawn too early (during the α \alpha α -phase), the measured plasma concentration will be extremely high and will not correlate with the drug concentration at the site of action.

Digoxin: Distribution takes 6 to 8 hours 6\text{ to }8\text{ hours} 6 to 8 hours . Serum levels must be drawn at least 6 to 8 hours 6\text{ to }8\text{ hours} 6 to 8 hours (ideally 12 hours 12\text{ hours} 12 hours ) post-dose.

Vancomycin: Distribution takes 1 to 2 hours 1\text{ to }2\text{ hours} 1 to 2 hours . Trough concentrations are drawn within 30 minutes 30\text{ minutes} 30 minutes prior to the next dose.

Step-by-Step Worked Clinical Example

A 70 kg 70\text{ kg} 70 kg female patient is currently taking Phenytoin Sodium capsules ( S = 0.92 S = 0.92 S = 0.92 ) at a dose of 300 mg/day 300\text{ mg/day} 300 mg/day ( F = 1.0 F = 1.0 F = 1.0 ). Her steady-state phenytoin concentration is measured to be 10 mcg/mL 10\text{ mcg/mL} 10 mcg/mL ( 10 mg/L 10\text{ mg/L} 10 mg/L ). Her estimated Michaelis constant ( K m K_m K m ​ ) is 5 mg/L 5\text{ mg/L} 5 mg/L .

Calculate the active daily drug rate ( R R R ) currently administered: R = 300 mg/day ⋅ 0.92 ⋅ 1.0 = 276 mg/day R = 300\text{ mg/day} \cdot 0.92 \cdot 1.0 = 276\text{ mg/day} R = 300 mg/day ⋅ 0.92 ⋅ 1.0 = 276 mg/day

Calculate the patient's individual maximum metabolic rate ( V m a x V_{max} V ma x ​ ): V m a x = R ⋅ ( K m + C s s ) C s s = 276 mg/day ⋅ ( 5 mg/L + 10 mg/L ) 10 mg/L = 414 mg/day V_{max} = \frac{R \cdot (K_m + C_{ss})}{C_{ss}} = \frac{276\text{ mg/day} \cdot (5\text{ mg/L} + 10\text{ mg/L})}{10\text{ mg/L}} = 414\text{ mg/day} V ma x ​ = C ss ​ R ⋅ ( K m ​ + C ss ​ ) ​ = 10 mg/L 276 mg/day ⋅ ( 5 mg/L + 10 mg/L ) ​ = 414 mg/day

Determine the new Phenytoin Sodium dose required to achieve a target C s s C_{ss} C ss ​ of 15 mcg/mL 15\text{ mcg/mL} 15 mcg/mL : R n e w = V m a x ⋅ C t a r g e t K m + C t a r g e t = 414 mg/day ⋅ 15 mg/L 5 mg/L + 15 mg/L = 310.5 mg/day R_{new} = \frac{V_{max} \cdot C_{target}}{K_m + C_{target}} = \frac{414\text{ mg/day} \cdot 15\text{ mg/L}}{5\text{ mg/L} + 15\text{ mg/L}} = 310.5\text{ mg/day} R n e w ​ = K m ​ + C t a r g e t ​ V ma x ​ ⋅ C t a r g e t ​ ​ = 5 mg/L + 15 mg/L 414 mg/day ⋅ 15 mg/L ​ = 310.5 mg/day

Convert the active rate to the Phenytoin Sodium capsule dose: New Capsule Dose = R n e w S = 310.5 mg/day 0.92 ≈ 337.5 mg/day \text{New Capsule Dose} = \frac{R_{new}}{S} = \frac{310.5\text{ mg/day}}{0.92} \approx 337.5\text{ mg/day} New Capsule Dose = S R n e w ​ ​ = 0.92 310.5 mg/day ​ ≈ 337.5 mg/day

Clinical Recommendation: The pharmacist would round this to 340 mg/day 340\text{ mg/day} 340 mg/day (administered as a combination of 300 mg 300\text{ mg} 300 mg and 40 mg 40\text{ mg} 40 mg capsules).